Alzheimer's Disease Clinical Trials: A Phase II Study to Assess the Safety, Tolerability and Efficacy of Xanamem™ in Subjects With Mild Dementia Due to AD (XanADu) | Alzheimer's, ADHD, Autism, Brain Injury Treatment, Mood Disorders New Jersey: The NeuroCognitive Institute

Alzheimer’s Disease Clinical Trials: A Phase II Study to Assess the Safety, Tolerability and Efficacy of Xanamem™ in Subjects With Mild Dementia Due to AD (XanADu)

XanADu: A Phase II, Double-Blind, 12-Week, Randomized, Placebo-Controlled Study to Assess the Safety, Tolerability and Efficacy of XanamemTM in Subjects With Mild Dementia Due to Alzheimer’s Disease (AD)

This XanADu Phase II study in mild Alzheimer’s Disease (AD) is to assess the safety, tolerability and efficacy of XanamemTM in subjects with mild dementia due to Alzheimer’s Disease. Subjects will be randomized to receive either 10mg once daily XanamemTM or Placebo at a 1:1 ratio in a double-blinded fashion.

This is a Phase II, randomised, multi-center, double-blind, placebo-controlled proof-of-concept study to assess the safety, tolerability and efficacy of oral XanamemTM once daily in adult subjects with mild dementia due to Alzheimer’s Disease.

Qualified participants for this study must be:

  • Adults 50 years and older with suspected mild AD
  • With a caregiver or family member who can assist the patient and is willing to attend the study visits along with the patient
  • Willing to take the daily study medication
  • Stable in their medical conditions and medications
  •  

    The overall study duration for an individual subject will be 17 to 20 weeks, including a screening period of one to 4 weeks, a double-blind treatment period of 12 weeks, and a follow-up period of 4 weeks. The total duration of the study is expected to be 2 years.

    If you’d like to enroll to this clinical trial, complete the form below and we’ll get back to you:

    Name:*
    Phone:*
    -
    E-mail:*
    Preferred way to contact you:*
    Word Verification:

    For more information, please call Estela Soniel at (973) 398 2900.  You can also send an email to es@neuroci.com.

    ClinicalTrials.gov Identifier: NCT02727699